INTRODUCTION
Managing type 2 diabetes (T2D) is a challenging task due to the continual decline in beta-cell function that occurs. This progressive debilitating condition ultimately mandates the use of insulin in most, if not all patients [1] . Timely initiation and active intensification of insulin is highly recommended to decrease the risk of longterm complications [2] . The American Diabetes Association recommends a target glycated hemoglobin (HbA 1c ) level of \7.0% as an established standard of good glycemic control [3] . Despite these guidelines, it has been observed that initiation and intensification of insulin in routine clinical practice is often delayed over fears of hypoglycemia, weight gain and effects on patients' quality of life (QoL) [1, 4] . Other factors such as insulin availability, needle phobia and economic considerations are also possible barriers that can have a significant impact on patient adherence to treatment [5] .
Conventional basal insulins, such as neutral protamine Hagedorn (NPH) and insulin glargine have variable absorption kinetics resulting in increased within-patient blood glucose variability and an associated risk of hypoglycemia [6, 7] . Also, the weight gain associated with conventional insulin therapy may increase blood pressure and worsen lipid profiles [8] . The development of long-acting basal insulin analogs, such as insulin detemir (IDet), with improved pharmacokinetics has been shown to have a positive effect on the balance between effective glycemic control and hypoglycemic risk [9] . IDet is able to closely mimic endogenous insulin secretion and has a prolonged timeaction profile due to its self-association and albumin-binding properties [10] . It is prescribed once-or twice-daily as an adjunct to oral antidiabetic drugs (OADs), glucagon-like peptide-1 analogs or as combination therapy with shortor rapid-acting insulins [11] . Previously, it has been demonstrated that IDet therapy results in lower within-subject variability of fasting plasma glucose (FPG) when compared with NPH insulin therapy [12] . Also, the effectiveness of glucose control with IDet has been observed with a reduced risk of hypoglycemia and no concerns about weight gain [13, 14] .
The clinical benefits of insulin analogs, including IDet, could become an integral part of managing T2D, a disease that has reached epidemic proportions worldwide [15] . Developing countries from the Near East region face a serious socioeconomic burden of increasing diabetes incidence. According to the International Diabetes Federation, in 2012, the prevalence of diabetes in Israel, Jordan, Lebanon and Pakistan was 7.85%, 11.62%, 17.04% and 7.89%, respectively [15] . Additionally, Lebanon is listed among the top 10 countries for diabetes prevalence worldwide [16] . Active measures to control and manage this disease are warranted. In order to increase awareness and provide appropriate guidance on T2D management the availability of local clinical data is essential. This 24-week observational study was thus conducted in T2D patients from four Near East Countries (Israel, Lebanon, Jordan and Pakistan) with an aim to evaluate the post-authorization experience with IDet in combination with OADs. Additionally, hypoglycemia due to the fasting regimen, Ramadan, was also reported. The incidence of adverse drug reactions (ADRs) was reported as the secondary safety objective. 
METHODS

Study Design
RESULTS
Patient Disposition
Of the 2,155 patients enrolled, 2,106 (97.7%) were exposed to the study drug. 
Insulin Dose
Mean (±SD) IDet dose at baseline was 0.20 ± 0.09 U/kg (15.6 ± 7.1 U/day), titrated up to 0.34 ± 0.14 U/kg (27.1 ± 11.4 U/day) by Week 24.
Hypoglycemia
Overall, major, minor and nocturnal hypoglycemic events and hypoglycemic events due to the fasting regimen, Ramadan, are reported in Table 2 
Adverse Drug Reactions
A total of 9 ADRs were reported in 9 patients (0.4%) during the study. Of these, one event in one patient was a serious ADR of chronic renal failure. In all, 12 treatment emergent adverse events were reported in 11 patients (0.5%). Of the 6 ADRs that led to discontinuation of IDet, 5 events (3 drug hypersensitivity/drug allergy; 1 pruritus; 1 drug eruption) were considered probably related to IDet, while one event of bone pain was considered possibly related to IDet. These events were mild to moderate in intensity.
Body Weight
Mean body weight did not change significantly from baseline (80.5 ± 13.8 kg) to Week 24 (80.4 ± 13.5 kg, p = 0.567).
Glucose Control
Mean HbA 1c levels improved significantly from 9.6 ± 1.6% at baseline to 7.6 ± 1.1% at Week 24 (mean change, -2.0 ± 1.6%, p\0.0001) ( Table 3 ).
DISCUSSION
Previously, it has been established that adding basal insulin to existing OAD therapy is an effective treatment strategy to manage uncontrolled T2D [17] . This study assessed the effects of IDet in combination with OADs in patients with T2D from Israel, Lebanon, Jordan and Pakistan. Introducing IDet therapy was well tolerated and resulted in marked improvements in glucose control after 24 weeks.
Baseline glycemic control in this cohort was poor. The average baseline HbA 1c level was 9.6%, while FPG and post-breakfast PPPG levels were 201.5 mg/dL and 264.2 mg/dL, respectively. This calls for an imperative need to design and implement more aggressive strategies to optimize T2D management in of the three most recent FPG levels. These improvements were seen alongside a low risk of hypoglycemia. As an expected outcome with first-time insulin initiation, there was a marginal increase in the rate of overall hypoglycemia from baseline to Week 24.
However, the incidence of major hypoglycemia was lower at Week 24 compared with baseline. The incidence of major hypoglycemia could be reduced due to initial responses to a change in therapy. Also, this study included only insulin-naïve patients who have a much lower rate of hypoglycemia compared with prior insulin users [18] . Nevertheless, we also acknowledge that a recall bias may have been introduced that could have masked the actual incidence of hypoglycemia.
The clinical safety and efficacy of treatment was demonstrated without administering high doses of IDet (0.20 U/kg to 0.34 U/kg) throughout the study period. Although the actual IDet dose in this study was lower than that reported in interventional trials [19, 20] , a significant change in glycemic control was observed. This positive response to therapy could also encourage physicians to resort to more active therapy intensification, leading to enhanced management of T2D.
Previously, it has been reported that every 2.5% decrease in HbA 1c is associated with a weight gain of *5 kg [21] . In contrast, average body weight remained fairly constant in our study despite a significant 2.0% decrease in mean HbA 1c level. Raslová et al. [22] also demonstrated that patients on IDet experienced less weight gain than those on NPH insulin in a pooled analysis of 900 patients with T2D. Several theories have been proposed to justify the low weight gain observed with IDet therapy. The low glucose variability reported with IDet therapy may minimize defensive snacking resulting in decreased weight gain. Also, IDet may induce the satiety signaling mechanism in the central nervous system or suppress adipogenesis in the peripheral tissues due to its albumin-binding properties [23] . IDet has a prolonged therapeutic action owing to its strong tendency to self-associate and remain highly bound to albumin in the subcutaneous depot [24] . Nevertheless, the exact mechanism of action resulting in low weight gain following
IDet therapy has yet to be elucidated. The United Kingdom Prospective Diabetes study demonstrated that 53% of patients treated with sulfonylurea monotherapy required insulin over a period of 6 years [25] .
The gradual decline in beta-cell mass and function in patients with T2D is correlated with an increase in HbA 1c levels, even after the use of more than one OAD [26] . Hence, insulin therapy becomes mandatory for all patients.
However, intensification with insulin therapy also increases the risk of hypoglycemia. Our study demonstrates that initiating IDet therapy effectively enhances glycemic control, without increasing the risk of hypoglycemia and weight gain, in line with the data from randomized controlled trials [19, 27] . 
CONCLUSION
In summary, the results of this observational study in the Near East region countries showed that treatment initiation with a long-acting basal analog, IDet, in combination with OAD therapy, can be a safe and effective treatment strategy for T2D patients.
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